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The discovery of three previously unknown kinases that
are essential for signaling in response to tumour
necrosis factor and interleukin-1 has provided the
missing link in the pathway that activates inflammatory
genes.
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Inflammation disorders, such as rheumatoid arthritis,
asthma and inflammatory bowel disease, can be consid-
ered as ‘gene expression diseases’ in which the pro-
inflammatory gene program of the organism is aberrantly
activated. The complexity of the inflammatory phenotype
can be attributed to the induction of the expression of a
vast number of proteins with distinct activities, which
together cause the various molecular and cellular events
that distinguish normal tissue from inflamed tissue. 
A hallmark of many genes that are switched on in inflam-
matory diseases is that their expression can be induced by
the cytokines tumor necrosis factor (TNF) and inter-
leukin-1 (IL-1). Increased levels of these two cytokines
have been linked to numerous inflammatory diseases; in
addition, TNF-neutralizing antibodies have been effica-
cious in the treatment of rheumatoid arthritis and inflam-
matory bowel disease [1]. Upon binding to their
cell-surface receptors, both TNF and IL-1 activate a cyto-
plasmic form of the transcription factor NF-κB [2,3].
DNA-binding motifs for NF-κB are found in the promot-
ers and enhancers of more than 50 genes that are known to
be activated upon inflammation [4], and in most cases the
induction of these genes has been shown to rely on the
binding of activated NF-κB to their regulatory sequences.
One of the physiological roles of NF-κB is to induce the
expression of defense genes rapidly upon life-threatening
conditions, such as viral and bacterial infections or physi-
cal stress. This transcription factor is particularly suited
for such a function because it is found in almost every
type of cell in a ‘pre-made’ form in the cytoplasm, where
it is held in an inactive protein complex with its inhibitor,
IκB. In chronically inflamed tissue, in which external
pathogenic stimuli seem to be absent, TNF and IL-1 act
as the primary endogenous inducers of NF-κB. When
cells are exposed to TNF or IL-1, a cascade of events
leads to the phosphorylation and subsequent degradation
of IκB with the result that NF-κB is then liberated to
enter the nucleus and activate gene expression [2,3]. 
Although the basic principle of NF-κB regulation was
understood several years ago [5], it was more difficult to
elucidate the mechanism of activation of NF-κB in the
cytoplasm upon triggering the cell-surface receptors for
TNF and IL-1. More detailed studies revealed that the
IκB inhibitor is removed from NF-κB by conjugation of
IκB to ubiquitin and its subsequent proteasome-depen-
dent proteolysis. This two-step process is triggered by the
phosphorylation of two serine residues in the amino-ter-
minal portion of IκB proteins. Many earlier studies pro-
posed the involvement of known kinases, but none of
these kinases could match the requirements for an IκB
kinase. In a 1996 study, biochemical characterization
revealed that the actual IκB kinase is apparently con-
tained within a large 600–700 kDa complex [6], but the
study gave no clue as to its identity.
Other labs have tried to unravel the pathway leading to
NF-κB activation by starting from the TNF and IL-1
receptors at the cell surface. Using the intracellular
domains of these receptors in biochemical purification
studies and yeast two-hybrid cloning analysis, recent years
have led to the discovery of several novel proteins, includ-
ing protein kinases, that are recruited to the cytoplasmic
portion of the receptors and thereby relay the activation
signal towards IκB ([7–10] and see below). Only the past
few months may have seen the conclusion of this puzzle,
with the discovery of previously unknown protein kinases
that eventually allow us to follow the complete TNF/IL-1
signaling pathway from the cell surface into the cell
nucleus. In this dispatch, the initial separate stages and
the common steps of the TNF and IL-1 signaling path-
ways as they appear after the recent seminal discoveries
(Figure 1) will be discussed. 
The TNF receptor (TNFR) subtype that plays a predom-
inant role in the pro-inflammatory actions of TNF is
TNFR1 [7]. Binding of the trimeric TNF ligand to the
extracellular domain of TNFR1 induces aggregation of
the death domains (DDs) — protein–protein interaction
motifs — within the cytoplasmic portion of the receptor.
The oligomerized DDs of the receptor act as a scaffold for
the assembly of a signaling complex containing at least
three different protein components: the TNFR-associated
death-domain protein, TRADD; the TNFR-associated
factor 2, TRAF2; and receptor-interacting protein, RIP
[11–13]. TRADD itself has a DD through which it multi-
merizes and associates with the DDs of the TNFR, acting
as an adaptor molecule to recruit the other two compo-
nents, TRAF2 and RIP. TRAF2 associates with the
amino-terminal half of TRADD, whereas RIP interacts
through its own DD with the DD of TRADD. TRAF2
and RIP also interact with each another, possibly stabiliz-
ing the complex. Of the three proteins in this signaling
complex, only RIP has a known intrinsic enzymatic activ-
ity as it contains an amino-terminal serine/threonine-spe-
cific kinase domain. Although RIP is essential for NF-κB
induction by TNF, its kinase activity does not appear to
be required for this function [14]. More experimental evi-
dence is required, however, to conclusively rule out a
direct involvement of the RIP kinase domain.
TRAF2 is a member of a new family of signaling proteins
that is characterized by the presence of a conserved TRAF
domain of approximately 230 amino acids in the carboxy-
terminal portion, and multiple zinc-finger motifs within
the amino-terminal half. The TRAF domain mediates
homotypic and heterotypic interactions and is also
involved in binding to other signaling molecules and
members of the TNFR superfamily. Six TRAF proteins
have been identified to date that are involved in signaling
by various TNFR superfamily members.
Although the IL-1 receptor (IL-1R) is entirely unrelated
in sequence to members of the TNFR superfamily, NF-
κB activation by IL-1 also involves a TRAF protein. Acti-
vation of the IL-1R by IL-1 induces receptor aggregation
and full activation requires an accessory membrane-span-
ning protein, AcP. Like the TNFR, the activated IL-
1R–AcP complex recruits a cytoplasmic complex of a
serine/threonine kinase and a TRAF protein — IL-1R-
activated kinase (IRAK) [15] and TRAF6 [16], respec-
tively. This raises the issue of how the unrelated
receptors use their specific signaling complexes —
TRADD–RIP–TRAF2 for TNFR1, and IRAK–TRAF6
for the IL-1R–AcP receptor complex — to trigger phos-
phorylation of IκB on the same serine residues, when the
kinases RIP and IRAK are unrelated and clearly do not
phosphorylate IκB directly.
The first signaling protein common to TNF and IL-1
pathways emerged as a novel mitogen-activated protein
kinase kinase kinase (MAPKKK) called NF-κB-inducing
kinase (NIK), which was identified in a yeast two-hybrid
screen for TRAF2-interacting proteins [17]. NIK, which
can also interact with TRAF6 [18], activates NF-κB when
overexpressed, and a kinase-inactive NIK mutant protein
blocks NF-κB activation mediated both by TNF and IL-1
treatment and TRAF2 and TRAF6 overexpression. These
and other observations place NIK downstream of the
TRAFs and at a point at which the TNF and IL-1 signal-
ing pathways converge.
The link between NIK, which alone cannot phosphorylate
IκB, and the signal-induced phosphorylation of IκB has
been established by the discovery of a NIK-interacting
protein kinase, termed IκB kinase α (IKK-α), in a yeast
two-hybrid screen using NIK as bait [19]. The same
protein was discovered as a component of a purified IKK
complex [20,21]. The kinase, which has a conserved
helix–loop–helix motif, had been cloned in previous
studies but its function remained unknown [22]. IKK-α
can phosphorylate various IκB proteins at the critical
serine residues and apparently acts in a complex with NIK
to phosphorylate NF-κB-bound IκB, thus triggering the
degradation of the inhibitor. 
An expressed sequence tag (EST) database search [20]
and protein purification studies [21,23] revealed the exis-
tence of a second IκB kinase, termed IKK-β, which shares
more than 50% identity with IKK-α [24]. Overexpression
of both IKKs activates NF-κB and kinase-inactive forms
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Figure 1
The pro-inflammatory signal transduction pathway. For abbreviations of
signaling components, see text; p50 and p65 are the two DNA-binding











































function as transdominant negative mutants. Consistent
with a role for these kinases in cytokine signaling, IKK
activities are stimulated upon treatment of cells with
TNF. IKK-α and IKK-β can each form homodimers but
seem to prefer to form heterodimers. The IKK-αβ het-
erodimer binds tightly to NIK, forming an unusual signal-
ing complex composed of three distinct kinases. A major
focus of research now will be to understand how NIK is
activated in response to the assembly of upstream signal-
ing proteins on the receptors and how the signal is relayed
through a complex of three distinct kinases. With the
identification of the IKKs and NIK, a contiguous pathway
linking TNF and IL-1 signaling pathways from the cell
surface to the cytoplasmic NF-κB–IκB complex has finally
been outlined. The beauty of these pathways lies in the
fact that the components were shown to interact physi-
cally with their respective upstream or downstream part-
ners, providing the experimental basis for its revelation.
An obvious question is whether we now know all of the
essential components required for activation of NF-κB in
response to TNF (and IL-1). In support of this idea is the
fact that all presently known protein components can
physically interact with each other in turn:
TNF–TNFR1–TRADD–RIP–TRAF2 with NIK–IKKs
with IκB–NF-κB. Each of these protein–protein interac-
tions was sufficently strong to allow the identification of
the subsequent component by either biochemical purifica-
tion or using two-hybrid screening in yeast. Perhaps there
are more signaling components to be discovered that asso-
ciate peripherally with the known components and, for
example, allow branching into other signaling pathways.
Another component yet to be discovered is an E3 ligase
that specifically recognizes doubly phosphorylated IκB
and initiates its conjugation to ubiquitin and its subse-
quent degradation [25].
The TNF signaling pathway is less similar to a diffusion-
controlled enzymatic cascade and more like a linear signal-
relay system that extensively exploits tight physical
interactions of enzymatic and non-enzymatic components.
Why has this signal transduction pathway apparently
evolved away from a catalytic cascade towards a more stoi-
chiometric method of signal transfer? The TNF and IL-1
signaling pathways are a prime target for every kind of
invading bacterium or virus, as inhibition of NF-κB activa-
tion will potently immunocompromise the host. Whereas
viruses use their own proteins to overwhelm the cellular
defense systems, bacteria and other micro-organisms fre-
quently use low molecular-weight metabolites, such as
cyclosporin or rapamycin, to suppress the immune
response. If the NF-κB signaling system could be success-
fully blocked by such a small molecule during an infec-
tion, the affected organism would no longer survive. The
system must therefore be subject to immense selective
pressure to escape inhibition by small molecules. 
The peculiarities of the TNF signaling pathway may be
interpreted as a number of strategies that have evolved
either to protect the pathway from small-molecule inhibi-
tion or to kill the cell if the pathway gets blocked. (1)
The number of catalytic steps is minimized: empirical
data suggest that enzymes, which by nature are designed
to interact with small-molecule substrates, are better
targets for small-molecule inhibition than
protein–protein interaction surfaces. (2) Complex
protein–protein interactions  are exploited for signal
relay. (3) The pathway uses essential cellular enzymes
that have an important role in cell survival: if these
enzymes are hit by a small molecule, the cell will die
before it can propagate the intruder. The use of essential
enzymes may be the reason why IκB inactivation relies
on the ubiquitin–proteasome system, which also has an
important role in the regulation of cell-cycle progression.
In this context, it will be very interesting to study the
phenotypes of IKK and NIK null mutants. (4) NF-κB is
involved in an anti-apoptotic genomic response. As
reviewed recently [26], some cell types will die in
response to TNF if NF-κB activation is blocked. (5)
Tight enzymatic complexes are formed that may not be
easily accessible to small molecules: this could explain
why the IKKs are contained in a large complex of
700 kDa together with the NF-κB–IκB substrate and
presumably NIK. (6) Enzymatic activities are redundant:
the two IKKs seem to be functionally redundant and may
require distinct inhibitory molecules to be inactivated.
The newly discovered kinases in the TNF/IL-1 signaling
pathway — IKK-α, IKK-β and NIK — would be attractive
targets for the development of novel anti-inflammatory
drugs. Similarly, these kinases are interesting signaling
molecules for further study because of their ability to form
a trimer and also because the mechanism of stimulating
the kinase activity of NIK by apparently non-enzymatic
signaling proteins is as yet unknown. An intriguing possi-
bility is that transient contact with upstream regulators
might lead to a prolonged alteration of the activity state of
the NIK–IKK-α–IKK-β kinase trimer. Such ‘molecular
memory’ based on (auto)phosphorylation has been
observed in another system, in which it promotes
the long-lasting calcium-independent activation of
calcium/calmodulin-dependent protein kinase II, a major
component of the postsynaptic density in neurons [27].
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